This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Immunome’s 8K filing here.
Immunome Company Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Read More
- Five stocks we like better than Immunome
- How to Choose Top Rated Stocks
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- There Are Different Types of Stock To Invest In
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Why Are These Companies Considered Blue Chips?
- Despite Short-Term Risks Freeport McMoran Worth a Look
